Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Kris Wood
AddedMar 31, 2024
UpdatedMay 31, 2026
Kris Wood

Kris Wood

Co-Founder, Tavros Therapeutics

CrunchbaseLinkedIn

Kris Wood's Career

Tavros Therapeutics
Tavros Therapeutics

Durham, NC, US

Co-Founder
Celldom
Celldom

Durham, NC, US

Co-Founder

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Kris Wood's Career

Tavros Therapeutics
Tavros Therapeutics
Series B$28M172019Durham, NC, US
Co-Founder

Leadership at Tavros Therapeutics

Robert LongRobert LongBoard Member
Greg MossinghoffGreg MossinghoffCo-Founder
Eoin McDonnellEoin McDonnellCo-Founder

Similar to Tavros Therapeutics

Tavotek BiotherapeuticsTavotek BiotherapeuticsGwynedd, PA, USBiopharmaceuticals, Therapeuticsest. 2019Tavotek BiotherapeuticsGwynedd, PA, US · est. 2019

Tavotek: A biopharmaceutical company innovating therapies for oncology and autoimmune diseases.

Series B · $55M24
Treadwell TherapeuticsTreadwell TherapeuticsNew York City, NY, USOncology Drugsest. 2020Treadwell TherapeuticsNew York City, NY, US · est. 2020

Treadwell Therapeutics: A clinical-stage oncology firm developing innovative cancer treatments.

Series B · $118M44
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Synnovation TherapeuticsSynnovation TherapeuticsWilmington, DE, USOncology Therapiesest. 2021Synnovation TherapeuticsWilmington, DE, US · est. 2021

Synnovation Therapeutics: Precision oncology firm specializing in small molecule therapies for cancer.

Series A · $139M18
Celldom
Celldom
Seed$1.9M52016Durham, NC, US
Co-Founder

Leadership at Celldom

Zachary ForbesZachary ForbesCo-Founder
Benjamin YellenBenjamin YellenCo-Founder

Similar to Celldom

DeepcellDeepcellMenlo Park, CA, USSoftwareest. 2017DeepcellMenlo Park, CA, US · est. 2017

Deepcell: Pioneering single-cell analysis software for enhanced disease diagnosis and treatment.

Series B · $98M111
Cell MicrosystemsCell MicrosystemsDurham, NC, USCell Analysisest. 2010Cell MicrosystemsDurham, NC, US · est. 2010

US-based Cell Microsystems Inc, founded in 2010, specializes in direct-to-consumer retail sales.

Series B · $30M38
ExpressCellsExpressCellsPhiladelphia, PA, USCell Linesest. 2018ExpressCellsPhiladelphia, PA, US · est. 2018

ExpressCells customizes human cell lines for biological research and drug discovery using proprietary gene-editing tools.

Pre-Seed · $1.8M8
Single Cell TechnologySingle Cell TechnologySan Jose, CA, USAntibody Discoveryest. 2008Single Cell TechnologySan Jose, CA, US · est. 2008

Biotech firm, Single Cell Technology, develops tech for antibody analysis and offers contract services.

Angel · $323.8k13

Kris Wood's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · KakaoJB LEEJB LEECo-Founder · Kakao

People Similar to Kris Wood

Chris MyersChris MyersResearcherChris Bailey-KelloggChris Bailey-KelloggCo-Founder · Occulo HoldingsKristy SandersonKristy SandersonResearcherBrian StrahlBrian StrahlCo-Founder · EpiCypherKevin WhaleyKevin WhaleyCo-Founder · Mapp BiopharmaceuticalJustin BurnsJustin BurnsBoard Member · Prospective Research